Recent reports show many imported originator drugs are out of stock in hospitals while resale prices surge wildly outside medical systems, creating huge pressure on clinical supply chains.

We supply qualified Indian generics manufactured under CDSCO regulations. Our generics have consistent active pharmaceutical ingredients, dosage form and route of administration, supported by bioequivalence studies. Stable production capacity helps clients hedge supply shortage and price fluctuation risks.

• Generics are not identical to originator drugs. Clinical application requires professional medical evaluation. 

• B2B business inquiry only. Not for sale to individual patients.